Calcium signaling underlies much of physiology. Almost all the Ca2+ in the cytoplasm is
bound to buffers, with typically only∼ 1% being freely ionized at resting levels in most cells …

The heterocellular nature of the heart has been receiving increasing attention in recent
years. In addition to cardiomyocytes as the prototypical cell type of the heart, non-myocytes …

Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent and intractable
form of cardiac decompensation commonly associated with diastolic dysfunction. Here, we …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment
strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the …

Cardiac diseases, such as myocardial infarction and heart failure, have become a major
clinical problem globally. The accumulating data demonstrate that bioactive compounds with …

Heart failure (HF) patients often suffer from multiple comorbidities, such as diabetes, atrial
fibrillation, depression, chronic obstructive pulmonary disease, and chronic kidney disease …

Heart failure with preserved ejection fraction (HFpEF) accounts for at least half the cases of
heart failure, currently diagnosed. There are several cardiac and non-cardiac manifestations …

Haploinsufficiency of transcriptional regulators causes human congenital heart disease
(CHD); however, the underlying CHD gene regulatory network (GRN) imbalances are …

Heart failure with preserved ejection fraction (HFpEF) is a growing public health concern,
with rising incidence alongside high morbidity and mortality. However, the pathophysiology …

Background: Mutations in tafazzin (TAZ), a gene required for biogenesis of cardiolipin, the
signature phospholipid of the inner mitochondrial membrane, causes Barth syndrome …